Image by *spud* via Flickr
An experimental treatment in Spain has shown promising possibilities to rebuild breasts damaged by tumors with the use of fat taken from the patient’s abdomen, removing stem cells, then injecting them into the chest, in a process that takes from four to five hours and does not leave scars.
Five patients from Madrid were the first in Spain to undergo the pioneering operation performed at Gregorio Maranon in collaboration with three other European hospitals in Great Britain, Italy, and Belgium. Mesenchymal stem cells, adult stem cells with the ability to transform into different tissues, are the
Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori’s APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function
Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company’s European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction (heart attack or AMI), as Research Correspondence in the Journal of the American College of Cardiology. The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA) evaluating autologous ADRCs extracted with the Company’s proprietary Celution® System for
A blood sample databank under the China Marrow Donor Program (CMDP), was officially established Monday at Zhongguancun of Beijing.
The new databank is now the largest for Chinese people in the world, according to Hong Junling, deputy head of CMDP management center.
The databank includes information such as the names and gender of nearly one million donors and information about to which ethnic groups the donors come from, Hong said.
It also covers such medical information as blood types, gene types and health status of the donors.
The CMDP, launched in 2001 by the Red Cross Society of China, aims to help millions
While only a small portion of autism spectrum disorders (ASDs) can be traced to their genetic roots, those that can are most often part of Fragile X syndrome (FXS), the most commonly known single-gene cause of autism. FXS is associated with the loss of the FMR protein (FMRP) coded by the mental retardation gene 1, FMR1 gene.
While scientists understand the biochemical nuances of these mutations, their implications on neuronal development and function remain a mystery. To address this puzzle, HSCI Associate Faculty member Stephen Haggarty, PhD, reprogrammed a series of both mutated and non-mutated cells back into a stem
Stem cells could be responsible for some forms of aggressive thyroid tumors (ATC, anaplastic thyroid carcinoma). The discovery was made by a young group of biotechnologists, biologists, and doctors from the Endocrinology department of the General Hospital of the University of Palermo. In the study, published in Plos One, the researchers described a subset of tumor stem cells that were able to proliferate continuously and may be responsible for uncontrolled tumor growth. These cells are resistant to chemotherapy and explain why ATC is so highly fatal in such a short period of time. The